Publication | Closed Access

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Emetogenic ChemotherapyOncologyMedicineMetronomic TherapyDelayed Onset NauseaNeuropharmacologyPharmacotherapyMetronomic ChemotherapyPharmacology5-Ht3 Antagonists Ondansetron